XERS

Deeper under the surface of Xeris Biopharma Holdings Inc.'s 2023 Q3 balance sheet, few facets catch the eyes of a seasoned value investor. Let's delve into the rabbit hole of financial analysis, to unearth insights often overlooked by average punters. No place for dawdling, let's crunch the numbers!

The total assets stand hunky-dory at a whopping US$327,784,000, with a significant slice (approximately 52%) knotted in non-current assets. Substantial assets, you say? Indeed. But beware that the non-current portion is predominantly tied up in intangible assets worth US$112,475,000, which isn't cash to jazz up the coffers immediately. An insightful investor knows liquidity, like a swiss watch, is king!

Turning the lens to liabilities, it's no tea party either. The company is shouldering a long-term debt of US$190,423,000, a figure that wouldn't let a CEO sleep easy. The total liabilities exceed the asset base, breathing down at US$323,919,000. Green around the gills yet? It doesn't stop here.

Flip the coin, and the Equity doth not shine brighter. A comprehensive income/loss attributable to the parent company sits at a naughty US$-12,161,000, which is as appealing as a skunk at a lawn party in an investor’s guidebook. The equity base is a meager US$3,865,000, a far cry from the significant liabilities carried.

Sniffing around the cash flow statement, we discover a net cash outflow of US$-14,610,000 recorded from operating activities. Ideally, a growth-oriented biopharma company should be generating positive cash flows from operations.

But hold your horses before you write it off! The devil lies in the details. They posted revenues of US$48,320,000, depicting a competent revenue-generating dynamo. But operating expenses overshoot at US$53,233,000, casting a long shadow on the bottom line. Resultantly, the income/loss from continuing operations before tax worth US$48,320,000 dwindles down to a net income/loss of US$-12,189,000, akin to a bubble bursting.

Xeris Biopharma may seem like a bumpy ride ahead. But a wise investor knows that stock value isn't about fleeting figures but about learning to dance with volatility. With the right strategies and timing, potential high risks indeed could brew high rewards!

Remember, numbers never play hide n' seek. So, keep your eyes wide open and your wit about you when evaluating stocks like Xeris Biopharma. Happy investing!